Login / Signup

A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.

Yuichi NagakawaYuichi HosokawaHidetsugu NakayamaYatsuka SaharaChie TakishitaTetsushi NakajimaYousuke HijikataKazuhiko KasuyaKenji KatsumataKoichi TokuuyeAkihiko Tsuchida
Published in: Cancer chemotherapy and pharmacology (2017)
Concurrent IMRT with gemcitabine and S-1 for patients is feasible as NACRT for BR-A with low gastrointestinal toxicity. IMRT can be employed as a standard radiotherapy to provide more effective NACRT with powerful chemotherapy drugs.
Keyphrases